Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Preclinical Development: Overview01:28

Preclinical Development: Overview

Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
Drug Discovery: Overview01:26

Drug Discovery: Overview

Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
Clinical Trials: Overview01:11

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
Bioavailability Study Design: Single Versus Multiple Dose Studies01:11

Bioavailability Study Design: Single Versus Multiple Dose Studies

Bioavailability studies are essential for understanding how a drug is absorbed, distributed, metabolized, and excreted in the body. These studies assess the extent and rate at which the active pharmaceutical agent becomes available at the site of action. The design of bioavailability studies can involve single-dose or multiple-dose regimens, each with distinct advantages and limitations.Single-dose studies are the preferred approach due to their simplicity and reduced drug exposure for...
Structure-Activity Relationships and Drug Design01:28

Structure-Activity Relationships and Drug Design

Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence its...
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Optimal Weighted Tests for Replication Studies and the 'Two-Trials Rule' With Multiple Hypotheses.

Statistics in medicine·2026
Same author

The performance of latent class analysis for clustering multiple long-term conditions is robust to the impact of high-prevalence conditions.

Journal of clinical epidemiology·2026
Same author

A randomized controlled Phase I de-escalation trial of molnupiravir and nirmatrelvir/ritonavir combination for mild-moderate SARS-CoV-2 infection.

The Journal of antimicrobial chemotherapy·2026
Same author

The predictive power of first recruits to commercial trial performance.

BMC medical research methodology·2026
Same author

An evaluation of designs for Phase I/IIa dose-finding studies in Tuberculosis.

Statistical methods in medical research·2026
Same author

Adaptive trials in low back pain and osteoarthritis: How common are they and when should they be used? A systematic review from ClinicalTrials.gov.

Osteoarthritis and cartilage open·2026

Related Experiment Video

Updated: May 12, 2026

High-throughput Screening for Chemical Modulators of Post-transcriptionally Regulated Genes
09:44

High-throughput Screening for Chemical Modulators of Post-transcriptionally Regulated Genes

Published on: March 3, 2015

Planning multi-arm screening studies within the context of a drug development program.

James M S Wason1, Thomas Jaki, Nigel Stallard

  • 1Hub for Trials Methodology Research, MRC Biostatistics Unit, Cambridge, U.K. james.wason@mrc-bsu.cam.ac.uk

Statistics in Medicine
|March 27, 2013
PubMed
Summary

This study optimizes clinical trial screening by simultaneously testing multiple treatments. It finds that including many treatments is best when only one proceeds, but fewer are optimal when multiple can advance.

Keywords:
multi-arm multi-stage trialsoptimal designphase II trialsscreening trials

More Related Videos

Nano-Differential Scanning Fluorimetry for Screening in Fragment-based Lead Discovery
06:26

Nano-Differential Scanning Fluorimetry for Screening in Fragment-based Lead Discovery

Published on: May 16, 2021

Drug-induced Sensitization of Adenylyl Cyclase: Assay Streamlining and Miniaturization for Small Molecule and siRNA Screening Applications
09:39

Drug-induced Sensitization of Adenylyl Cyclase: Assay Streamlining and Miniaturization for Small Molecule and siRNA Screening Applications

Published on: January 27, 2014

Related Experiment Videos

Last Updated: May 12, 2026

High-throughput Screening for Chemical Modulators of Post-transcriptionally Regulated Genes
09:44

High-throughput Screening for Chemical Modulators of Post-transcriptionally Regulated Genes

Published on: March 3, 2015

Nano-Differential Scanning Fluorimetry for Screening in Fragment-based Lead Discovery
06:26

Nano-Differential Scanning Fluorimetry for Screening in Fragment-based Lead Discovery

Published on: May 16, 2021

Drug-induced Sensitization of Adenylyl Cyclase: Assay Streamlining and Miniaturization for Small Molecule and siRNA Screening Applications
09:39

Drug-induced Sensitization of Adenylyl Cyclase: Assay Streamlining and Miniaturization for Small Molecule and siRNA Screening Applications

Published on: January 27, 2014

Area of Science:

  • Clinical Trial Design
  • Pharmaceutical Development
  • Biostatistics

Background:

  • Screening trials identify promising interventions for large confirmatory trials.
  • Previous research focused on sequential testing of treatments.
  • Optimizing screening trial efficiency is crucial for drug development sponsors.

Purpose of the Study:

  • To investigate simultaneous multi-treatment screening trial designs.
  • To develop methods for finding optimal numbers of treatments and sample sizes per treatment.
  • To compare different screening and confirmatory trial progression strategies.

Main Methods:

  • Derivation of analytic formulae for expected patients to find a successful treatment.
  • Methodology for optimizing the number of simultaneous treatments and sample size per treatment.
  • Comparison of screening designs with single-treatment vs. multi-treatment confirmatory trials.

Main Results:

  • Simultaneous multi-treatment screening can be more efficient than sequential testing.
  • Optimal number of treatments depends on whether one or multiple treatments advance.
  • A large number of treatments is optimal when only one proceeds; fewer treatments are optimal when multiple can proceed.

Conclusions:

  • Simultaneous screening trial designs offer an efficient alternative to sequential testing.
  • The optimal design balances the number of treatments and sample size per treatment.
  • Findings provide practical guidance for planning efficient drug development screening phases.